Data for Thought
• Wealth Insight - Jun 2026
The blockbuster drug India can now actually afford
With Novo Nordisk's patent gone in India, a dozen generics have flooded in at a fraction of the price, and a market of 10 crore diabetics is waiting
01-Jun-2026•Value Research Team
Top Picks
NSE IPO: A business that is hard to fault
6 min read•By Lekisha Katyal
Welcome to the New Value Research!
2 min read•By Value Research
Aggressive Hybrid VS Balanced Advantage Funds
14 min read•By Value Research
New episodes every Friday
Growth that goes nowhere
Why every growing company isn't making its shareholders richer
Other Episodes
-
Trust and jargon are dangerous for investors
Retired bankers fell for this fund. Here is why you might too.
-
The average hides the saver
A record monthly total can keep rising even as the smallest savers, the ones it was meant to celebrate, give up and walk away
-
A fall is not a loss
A red number on your screen is not a loss. You make it permanent only by acting on it.
-
A fall is not a loss
A red number on your screen is not a loss. You make it permanent only by acting on it.
More stories from Wealth Insight June 2026
Explore the edition
3 min read•By Dhirendra Kumar
Good businesses. Better numbers.
20 min read•By Abhinav Goel and Lekisha Katyal
What a $100 barrel reveals about your stocks
4 min read•By Dhirendra Kumar
3 min read•By Mohammed Ekramul Haque
3 min read•By Value Research Team
5 min read•By Anand Tandon
5 min read•By Value Research Team
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
